83 related articles for article (PubMed ID: 27126094)
1. Prostate cancer: endogenous chemical castration.
McCoy OO; Prasad MM; Singer N
BMJ Case Rep; 2016 Apr; 2016():. PubMed ID: 27126094
[TBL] [Abstract][Full Text] [Related]
2. Significance of prostate-specific antigen kinetics after three-dimensional conformal radiotherapy with androgen deprivation therapy in patients with localized prostate cancer.
Fukuokaya W; Kim S; Natsuyama T; Matsuzaki K; Shiomi H; Kitoh H; Utsumi N; Kurosaki H; Inoue M; Akakura K
Int J Clin Oncol; 2018 Apr; 23(2):361-367. PubMed ID: 29151227
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
[TBL] [Abstract][Full Text] [Related]
4. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.
Khaksar SJ; Laing RW; Henderson A; Sooriakumaran P; Lovell D; Langley SE
BJU Int; 2006 Dec; 98(6):1210-5. PubMed ID: 17034501
[TBL] [Abstract][Full Text] [Related]
5. Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation.
Geara FB; Bulbul M; Khauli RB; Andraos TY; Abboud M; Al Mousa A; Sarhan N; Salem A; Ghatasheh H; Alnsour A; Ayoub Z; Gheida IA; Charafeddine M; Shahait M; Shamseddine A; Gheida RA; Khader J
Radiat Oncol; 2017 Sep; 12(1):149. PubMed ID: 28882187
[TBL] [Abstract][Full Text] [Related]
6. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
7. A comparison of early prostate-specific antigen decline between prostate brachytherapy and different fractionation of external beam radiation-Impact on biochemical failure.
Taussky D; Bedwani S; Meissner N; Bahary JP; Lambert C; Barkati M; Beauchemin MC; Ménard C; Delouya G
Brachytherapy; 2018; 17(2):277-282. PubMed ID: 29306674
[TBL] [Abstract][Full Text] [Related]
8. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
9. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
[TBL] [Abstract][Full Text] [Related]
11. Impact of neoadjuvant prostate-specific antigen kinetics on biochemical failure and prostate cancer mortality: results from a prospective patient database.
Foo M; Lavieri M; Pickles T
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):385-92. PubMed ID: 22652112
[TBL] [Abstract][Full Text] [Related]
12. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
Ogan K; Berger M; Ball R
J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
[No Abstract] [Full Text] [Related]
14. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
15. External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.
Cho E; Mostaghel EA; Russell KJ; Liao JJ; Konodi MA; Kurland BF; Marck BT; Matsumoto AM; Dalkin BL; Montgomery RB
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):236-43. PubMed ID: 25772183
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
17. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
18. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
20. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
Park Y; Park HJ; Jang WI; Jeong BK; Kim HJ; Chang AR
Radiat Oncol; 2018 Nov; 13(1):230. PubMed ID: 30470253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]